BALTIMORE, Md.–(BUSINESS WIRE)–Aug. September 2022–
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage biopharmaceutical company developing breakthrough therapies to treat severe and debilitating autoimmune and inflammatory diseases, announced a dose update of its fully funded Phase 2 clinical trial announced lead drug candidate MYMD-1 ® , an orally available next-generation TNF-alpha inhibitor, as a therapy for chronic inflammation associated with sarcopenia and frailty.
kAm%@ 52E6[ E96 EC:2= 92D 4@>A=6E65 5@D:?8 7@C E96 D64@?5 A2E:6?E 4@9@CE] %96 $276EJ #6G:6H r@>>:EE66 92D 4@?7:C>65 ?@ D276EJ @CE@I:4:EJ :DDF6D 2?5 92D G@E65 F?2?:>@ FD=JE@ 6D42=2E6 E@ E96 ?6IE 9:896C 5@D6 2?5 368:? 6?C@==:?8 E96 ?6IE 4@9@CE]k^Am
kAm“(6 2C6 A=62D65 H:E9 E96 8@@5 ?6HD E92E H6 H:== 36 AC@8C6DD:?8 @FC !92D6 a EC:2= :?E@ E96 ?6IE 5@D :?8 4@9@CE[ 8:G6? E92E |*|s\` 92D 366? H6==\E@=6C2E65 3J A2CE:4:A2?ED E@ 52E6[” D2:5 r9C:D r92A>2?[ |s[ !C6D:56?E[ s:C64E@C 2?5 r9:67 |65:42= ~77:46C @7 |J|s] “(6 4@?E:?F6 E@ 2?E:4:A2E6 677:424J 52E2 =2E6C E9:D J62C]”k^Am
kAm%96 !92D6 a >F=E:\46?E6C 5@F3=6\3=:?5[ A=2463@ 4@?EC@==65[ C2?5@>:K65 DEF5J W k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?
kAmk6>mp3@FE |J|s !92C>246FE:42=Dk^Am
kAmk^6>m |J|s !92C>246FE:42=D[ x?4] W}2D52Bi |*|sX[ 😀 2 4=:?:42= DE286 3:@A92C>2 4@>A2?J 56G6=@A:?8 8C@F?53C62<:?8 E96C2A:6D 7@C E96 EC62E>6?E @7 D6C:@FD 2?5 563:=:E2E:?8 2FE@:>>F?6 2?5 :?7=2>>2E@CJ 5:D62D6D] |J|s’D =625 4=:?:42= 42?5:52E6[ |*|s\`®[ 😀 2? @C2==J 2G2:=23=6 ?6IE\86?6C2E:@? %}u\2=A92 :?9:3:E@C H:E9 E96 A@E6?E:2= E@ EC2?D7@C> E96 H2J E92E %}u\2=A92 32D65 5:D62D6D 2C6 EC62E65] |*|s\`®[ H:E9 :ED D>2== >@=64F=6 56D:8?[ :>AC@G65 D276EJ AC@7:=6 2?5 23:=:EJ E@ 4C@DD E96 3=@@5 3C2:? 32CC:6C[ 92D E96 AC@>:D6 E@ AC@G:56 >62?:?87F= E96C2A6FE:4 D@=FE:@?D E@ A2E:6?ED ?@E D6CG65 3J 4FCC6?E %}u\2=A92 :?9:3:E@CD 2?5 2D 2 A@E6?E:2= E96C2AJ 7@C r}$\32D65 :?7=2>>2E@CJ 2?5 2FE@:>>F?6 5:D62D6D] |*|s\` 92D 56>@?DEC2E65 E96 A@E6?E:2= E@ D=@H E96 28:?8 AC@46DD 2?5 6IE6?5 962=E9J =:76DA2?]% 96 4@>A2?J 😀 6G2=F2E:?8 |*|s\`® 😕 !92D6 a DEF5:6D 7@C D2C4@A6?:2^7C2:=EJ[ 2 C6DF=E @7 E96 28:?8 AC@46DD[ 2D H6== 2D 62C=J\DE286 EC:2=D 7@C C96F>2E@:5 2CE9C:E:D W#pX[ H:E9 E96 A@E6?E:2= E@ 6IA2?5 :?E@ @E96C 2AA=:42E:@?D] |J|s’D D64@?5 E96C2A6FE:4 42?5:52E6 😀 $FA6C2\rqs[ 2 ?@G6=[ DJ?E96E:4[ ?@?\E@I:4 42??23:5:@= WrqsX 2?2=@8 E92E 😀 g___ E:>6D >@C6 A@E6?E 2 rqa 28@?:DE W24E:G2E@CX E92? A=2?E\32D65 rqs] x? 255:E:@? E@ :ED A@E6?E:2= C@=6 😕 >2?28:?8 255:4E:@?[ 2?I:6EJ[ 49C@?:4 A2:? 2?5 D6:KFC6D[ $FA6C2\rqs 92D 2=D@ 366? D9@H? E@ 92G6 2?E:\:?7=2>>2E@CJ 67764ED] u@C >>C6 :?7@C>2E:@?[ G:D:E k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?
kAmk6>mr2FE:@?2CJ $E2E6>6?E #682C5:?8 u@CH2C5\{@@<:?8 $E2E6>6?EDk^Am
kAmk^6>m %9:D AC6DD C6=62D6 >2J 4@?E2:? 7@CH2C5\=@@<:?8 DE2E6>6?ED]%96D6 7@CH2C5\=@@<:?8 DE2E6>6?ED :?G@=G6[ F?46CE2:?E:6D 2?5 @E96C 724E@CD H9:49 >2J 42FD6 24EF2= C6DF=ED[ A6C7@C>2?46 @C 249:6G6>6?ED E@ 36 >2E6C:2==J 5:776C6?E 7C@> 2?J 6IA64E65 7FEFC6 C6DF=ED[ A6C7@C>2?46[ @C 249:6G6>6?ED] u@CH2C5\=@@<:?8 DE2E6>6?ED DA62< @?=J 2D @7 E96 52E6 E96J 2C6 >256 2?5 ?@?6 @7 |J|s ?@C :ED 277 :=:2E6D 2DDF>6 2?J 5FEJ E@ FA52E6 7@CH2C5\=@@<:?8 DE2E6>6?ED](@C5D DF49 2D Q2?E:4:A2E6[Q Q36=:6G6[Q Q4@F=5[Q Q6DE:>2E6[Q Q6IA64E[Q Q>2J[Q QA=2?[Q QH:==[Q QH@F=5VV 2?5 @E96C D:>:=2C 6IAC6DD:@?D 2C6 :?E6?565 E@ :56?E:7J E96D6 7@CH2C5\=@@<:?8 DE2E6>6?ED] x>A@CE2?E 724E@CD E92E 4@F=5 42FD6 24EF2= C6DF=ED E@ 5:776C >2E6C:2==J 7C@> E9@D6 :?5:42E65 3J DF49 7@CH2C5 \=@@<:?8 DE2E6>6?ED :?4=F56[ H:E9@FE =:>:E2E:@?i E96 E:>:?8 @7[ 2?5 |J|s’D 23:=:EJ E@[ @3E2:? 2?5 >2:?E2:? C68F=2E@CJ 2AAC@G2=D 7@C 4=:?:42= EC:2=D @7 |J|s’D A92C>246FE:42= 42?5:52E6Dj E96 E:>:?8 2?5 C6DF=ED @7 |J|s’D A=2??65 4=:?:42= EC:2=D 7@C :ED A92C>246FE:42= 42?5:52E6Dj E96 2>@F?E @7 7F?5D |J|s C6BF:C6D 7@C :ED A92C>246FE:42= 42?5:52E6Dj :?4C62D65 =6G6=D @7 4@>A6E:E:@?j 492?86D 😕 A@=:E:42=[ 64@?@>:4 @C C68F=2E@CJ 4@?5:E:@?D 86?6C2==J 2?5 😕 E96 >2C<6ED 😕 H9:49 |J|s @A6C2E6Dj |J|s’D 23:=:EJ E@ C6E2:? 2?5 2EEC24E D6?:@C >2?286>6?E 2?5 @E96C <6J 6>A=@J66Dj |J|s’D 23:=:EJ E@ BF:4<=J 2?5 67764E:G6=J C6DA@?5 E@ ?6H E649?@=@8:42= 56G6=@A>6?EDj |J|s’D 23:=:EJ E@ AC@E64E :ED EC256 D64C6ED @C @E96C AC@AC:6E2CJ C:89ED[ @A6C2E6 H:E9@FE :?7C:?8:?8 FA@? E96 AC@AC:6E2CJ C:89ED @7 @E96CD 2?5 AC6G6?E @E96CD 7C@> :?7C:?8:?8 @? |J|s’D AC@AC:6E2CJ C:89EDj 2?5 E96 :>A24E @7 E96 @?8@:?8 r~’xs\`h A2?56>:4 @? |J|s’D C6DF=ED @7 @A6C2E:@?D[ 3FD:?6DD A=2? 2?5 E96 8=@32= 64@?@>J] p 5:D4FDD:@? @7 E96D6 2?5 @E96C 724E@CD H:E9 C6DA64E E@ |J|s 😀 D6E 7@CE9 😕 E96 r@>A2?JVD p??F2= #6A@CE @? u@C>`_\z 7@C E96 J62C 6?565 s646>36C b`[ a_a`[ 7:=65 3J |J|s @? |2C49 b`[ a_aa[ 2D >2J 36 DFAA=6>6?E65 @C 2>6?565 3J E96 r@>A2?J’D “F2CE6C=J #6A@CED @? u@C> `_\”] u@CH2C5\=@@<:?8 DE2E6>6?ED DA62< @?=J 2D @7 E96 52E6 E96J 2C6 >256 2?5 |J|s 5:D4=2:>D 2?J : ?E6?E:@? @C @3=:82E:@? E@ C6G:D6 2?J 7@CH2C5\=@@<:?8 DE2E6>6?ED[ H96E96C 2D 2 C6DF=E @7 ?6H :?7@C>2E:@?[ 7FEFC6 6G6?ED @C @E96CH:D6]k^Am
kAm’:6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6 ^a_aa_ha___dbbg^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_ha___dbbg^6?^k^2mk^ Am
kAmr~}%pr%ix?G6DE@C r@?E24Eik^Am
kAm#@36CE $492EKk^Am
kAmWeceX ca`\hdabk^Am
kAmk2 9C67lQ>2:=E@iCD492EKo>J>5]4@>|65:2QmCD492EKo>J>5]4@>|65:2k^2m r@?E24Eik^Am
kAm|:<6q6J6Ck^Am
kAm$2> qC@H?[ x?4]k^Am
kAmWb`aX he`\ad_ak^Am
kAmk2 9C67lQ>2:=E@i|:<6q6J6CoD2>3C@H?]4@>Qm|:<6q6J6CoD2>3C@H?]4@>k^2mk^Am
kAmzt*(~#si |p#*{p}s &}x%ts $%p%t$ }~#%wp|t#xrpk^Am
kAmx}s&$%#* zt*(~#si #t$tp#rw r{x}xrp{ %#xp{$ qx~%trw}~{~v* ~%wt# wtp{%w wtp{ %w !wp#|prt&%xrp{ vt}t#p{ wtp{%w ~%wt# $rxt}rt $rxt}rtk^Am
kAm$~&#rti |J|s !92C>246FE:42=D[ x?4]k^Am
kAmr@AJC:89E qFD:?6DD (:C6 a_aa]k^Am
kAm!&qi _h^a_^a_aa _gi__ p|^sx$ri _h^a_^a_aa _gi_b p|k^Am
kAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_ha___dbbg^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@ >6^a_aa_ha___dbbg^6?k^2mk^Am
Copyright Business Wire 2022.